The Liquid-Solid Transition of Tau Protein:

Neurofibrillary tangles (NFTs), composed of aggregated and hyperphosphorylated Tau protein, represent a definitive neuropathological hallmark of Alzheimer's disease (AD) and related tauopathies. The classical model of direct nucleation-dependent polymerization from monomer to filament is increasingly recognized as insufficient, failing to explain critical observations such as the stereotypic spatiotemporal initiation of pathology, the prolonged pre-fibrillar phase of neuronal dysfunction, and the heterogeneous molecular composition of inclusions. This analysis posits that liquid-liquid phase separation (LLPS) of Tau is the indispensable, rate-limiting pre-assembly step that creates a concentrated biochemical crucible, thereby governing the pathological cascade. Within these metastable, liquid-like condensates, specific molecular perturbations—including disease-associated post-translational modifications (e.g., hyperphosphorylation at MTBR residues, acetylation), FTDP-17 mutations (e.g., P301L), and microenvironmental stressors (oxidative crosslinking, chaperone deficit)—catalyze an irreversible liquid-to-solid phase transition. This framework redefines NFT formation not as a stochastic aggregation event but as a misregulated phase transition, shifting the mechanistic focus from endpoint fibrils to the dynamic material properties of the precursor state. The evidentiary foundation for this paradigm is constructed from a rigorous, multi-scale synthesis of peer-reviewed global research. This includes in vitro biophysical reconstitution studies demonstrating direct visualization of Tau droplet formation and subsequent amyloidogenesis (e.g., Wegmann et al., Nat Cell Biol, 2020); cellular models employing FTDP-17 patient-derived iPSC neurons and optogenetic clustering that confirm forced condensation drives phosphorylation and insolubility; and correlative human neuropathological data from cryo-EM structures, proteomic analyses of biochemical fractions, and histological progression. The model provides a unified explanation for the selectivity of neuronal vulnerability, the lag between biochemical change and fibrillization, and the complex constituency of NFTs. Consequently, the primary therapeutic implication is a fundamental pivot: from strategies aimed solely at blocking monomer aggregation or disassembling fibrils, towards interventions designed to modulate the material state of Tau condensates—stabilizing their dynamic liquidity or preventing their pathological solidification. This represents a paradigm shift in neurodegenerative disease etiology, moving from a purely biochemical to a biophysical understanding of proteostatic failure.